FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a market perform rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Price Performance

NASDAQ:FGEN opened at $0.43 on Tuesday. The company has a market cap of $42.30 million, a price-to-earnings ratio of -0.17 and a beta of 0.71. FibroGen has a 1 year low of $0.33 and a 1 year high of $2.93. The stock’s 50 day simple moving average is $0.68 and its two-hundred day simple moving average is $1.22.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the prior year, the firm posted ($0.65) EPS. As a group, analysts anticipate that FibroGen will post -0.91 EPS for the current year.

Insider Transactions at FibroGen

In other news, insider Deyaa Adib purchased 22,123 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the acquisition, the insider now owns 82,123 shares of the company’s stock, valued at approximately $96,083.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.98% of the company’s stock.

Hedge Funds Weigh In On FibroGen

Several hedge funds have recently bought and sold shares of the business. Armistice Capital LLC increased its position in FibroGen by 23.7% during the 4th quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock valued at $8,654,000 after purchasing an additional 1,872,000 shares during the period. Acadian Asset Management LLC raised its holdings in shares of FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after purchasing an additional 860,854 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares during the period. Pennant Investors LP acquired a new position in FibroGen in the fourth quarter valued at approximately $681,000. Finally, XTX Topco Ltd purchased a new stake in FibroGen during the second quarter worth $424,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.